February 13, 2009 (FinancialWire) -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) (Current Market Cap: US$397.02 Mil.) has appointed David G. Gionco to the position of vice president, chief financial officer and treasurer. Gionco replaces Brian Hayden, who has been terminated as Savient's CFO.

Gionco joined Savient in 2006, where he most recently served as VP of corporate finance and controller. He has held various audit, corporate accounting, financial planning, finance and controller roles at companies including Medco, Merck & Co., Progenics Pharmaceuticals and Odyssey Pharmaceuticals, where he served as acting CFO and director of finance and controller before joining Savient.

East Brunswick, New Jersey-based Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Krystexxa for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data, according to the firm.

FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .

Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .

Copyright(C)2009 by financialwire.net, Inc. All rights reserved.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.